Teleflex Incorporated
NYSE•TFX
CEO: Mr. Liam J. Kelly
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1980-03-17
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
連絡先情報
550 East Swedesford Road, Suite 400, Wayne, PA, 19087-1603, United States
610-225-6800
時価総額
$4.68B
PER (TTM)
-14.3
26
配当利回り
1.3%
52週高値
$180.58
52週安値
$100.18
52週レンジ
順位29Top 17.8%
5.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$913.02M+19.45%
直近4四半期の推移
EPS
-$9.24-488.23%
直近4四半期の推移
フリーCF
$77.69M-62.97%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Revenue Growth Strong Nine months net revenues hit $2.39B USD, increasing 6.3% over prior period, driven by VI Business.
VI Acquisition Financing Acquisition contributed $101.8M revenue in nine months, financed via $1.14B in new borrowings.
Cash Position Stable Total cash, cash equivalents, and restricted cash ended at $381.3M USD as of September 28, 2025.
Operating Cash Flow Dip Operating cash flow from continuing operations dropped $246.6M USD for nine months compared to prior year.
リスク要因
Goodwill Impairment Hit Recognized $403.9M goodwill impairment charge for IU reporting unit during the third quarter of 2025.
Asset Impairment Recorded Recorded $100.0M impairment charge for Titan SGS assets due to revised lower sales forecasts.
Restructuring Charges High Incurred $117.6M restructuring charges in Q3 2025, including $100.0M asset impairment charge.
Tariff Impact Monitoring Enacted U.S. tariffs negatively impacted gross margins and cash flows for both three and nine months.
見通し
Corporate Separation Plan Actively advancing potential sale of NewCo following announced strategic separation decision in February 2025.
VI Integration Restructuring New VI Business integration plan estimates $36M to $44M total restructuring charges through expected completion 2028.
Future Savings Expected VI Business integration plan expects to begin realizing annual pre-tax savings of $24M to $30M in 2026.
同業比較
売上高 (TTM)
OSCR$11.70B
$4.98B
BRKR$3.44B
粗利益率 (最新四半期)
ARWR100.0%
ALKS86.9%
TGTX82.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| ARWR | $8.92B | 44.1 | 36.1% | 19.5% |
| KRYS | $8.35B | 41.9 | 18.2% | 0.1% |
| PCVX | $7.57B | -11.1 | -21.1% | 2.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.7%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年2月26日
EPS:$3.76
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月28日|提出日: 2025年11月6日|売上高: $913.02M+19.4%|EPS: $-9.24-488.2%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月29日|提出日: 2025年7月31日|売上高: $780.89M+4.2%|EPS: $2.77+62.9%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月30日|提出日: 2025年5月1日|売上高: $700.67M-5.0%|EPS: $2.08+550.0%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月28日|売上高: $3.05B+2.4%|EPS: $1.49-80.3%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月29日|提出日: 2024年10月31日|売上高: $764.38M+2.4%|EPS: $2.38-18.5%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月2日|売上高: $749.69M+0.9%|EPS: $1.70-28.3%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月3日|売上高: $737.85M+3.8%|EPS: $0.32-80.4%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月23日|売上高: $2.97B+6.6%|EPS: $7.58-2.1%予想を下回る